Integration of research in pharmacotherapy for addictive disease: where are we? Where are we going?
Integration of research in pharmacotherapy for addictive disease: where are we? Where are we going?
复制标题
成瘾疾病药物治疗研究的整合：我们在哪里？
DOI：
10.1080/10550889709511145
复制
发表时间：
1997
期刊：
影响因子：
--
通讯作者：
Shoptaw,S
中科院分区：
文献类型：
--
作者：
Ling,W;Shoptaw,S
NIDA和NIAAA为开发治疗药物和酒精依赖的新药所做的系统性努力，导致FDA最近批准LAAM用于阿片类药物依赖，纳洛酮用于酒精依赖，最近还批准了用于尼古丁依赖的鼻喷雾剂。本文综述了指导这些开发工作的当前策略，包括进一步检查潜在药物与滥用药物之间的相互作用，通过非药物干预提高药物疗效，以及开发更精确和有意义的研究结果指标。
Systematic efforts by NIDA and NIAAA to develop new medications for drug and alcohol dependence have resulted in recent FDA approval of LAAM for opiate dependence, naltrexone for alcohol dependence and, more recently, a nasal spray for nicotine dependence. This article reviews the current strategies that guide these development efforts, including further examination of the interactions between potential pharmacotherapeutic agents and the drugs of abuse, the enhancement of pharmacotherapeutic efficacy with non‐pharmacological interventions, and the development of more precise and meaningful measures of research outcome.